{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-017031","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.798709+00:00","generated_at":"2026-06-15T06:08:30.551048+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aadi Bioscience reports Q1 2023 FYARRO sales of $5.9M, net loss $15.2M; PRECISION 1 interim analysis expected end 2023","bullets":["FYARRO net product sales $5.9M, up 12% QoQ from $5.2M in Q4 2022 and $2.3M in Q1 2022.","Net loss $15.2M vs $13.9M in Q1 2022; cash $151.2M expected to fund operations into 2025.","PRECISION 1 trial enrolling evenly in TSC1/2 arms; >15 tumor types; interim efficacy analysis on 40 patients expected by year-end 2023.","Appointed Dr. Mohammad Hirmand to board; Phase 1/2 KRAS G12C combo trial with adagrasib expected to start dosing in Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-017031","json":"https://secwatch.observer/filing/0001628280-23-017031.json","markdown":"https://secwatch.observer/filing/0001628280-23-017031.md","text":"https://secwatch.observer/filing/0001628280-23-017031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023017031/0001628280-23-017031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023017031/aadi-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:08:30.551048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9aded7610223c3098b9c3355583eb6659d4df4b","claim":"Whitehawk Therapeutics, Inc. reported the quarter ended March 31, 2023 results: revenue $5.9 million, net income $15.2 million.","evidence_excerpt":"Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial Total 1Q 2023 revenue on FYARRO® sales of $5.9 million PRECISION 1 tumor agnostic trial enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented Interim analysis on 40 patients with appropriate","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023017031/0001628280-23-017031-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$5.9 million"},{"label":"Net income","value":"$15.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}